Skip to main content

Advertisement

Log in

Metastatic collecting duct carcinoma of the kidney responded to sunitinib

International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Collecting duct carcinoma (CDC) of the kidney is a rare and aggressive malignant tumor arising from the distal collecting tubules which has been shown to have a poor response to several kinds of systemic therapy. We present a case of metastatic CDC that responded favorably to a multiple tyrosine kinase inhibitor, sunitinib, achieving a partial response in both lung and skeletal metastases. To our knowledge, this is the first report showing therapeutic activity of sunitinib against CDC. Considering these findings, it would be worthwhile prospectively investigating the role of multiple tyrosine kinase inhibitors, particularly sunitinib, in the management of metastatic CDC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Srigley JR, Eble JN (1998) Collecting duct carcinoma of kidney. Semin Diagn Pathol 15:54–67

    PubMed  CAS  Google Scholar 

  2. Gollob JA, Upton MP, DeWolf WC et al (2001) Long-term remission in a patient with metastatic collecting duct carcinoma treated with taxol/carboplatin and surgery. Urology 58:1058

    Article  PubMed  CAS  Google Scholar 

  3. Milowsky MI, Rosmarin A, Tickoo SK et al (2002) Active chemotherapy for collecting duct carcinoma of the kidney: a case report and review of the literature. Cancer 94:111–116

    Article  PubMed  Google Scholar 

  4. Peyromaure M, Thiounn N, Scotté F et al (2003) Collecting duct carcinoma of the kidney: a clinicopathological study of 9 cases. J Urol 170:1138–1140

    Article  PubMed  Google Scholar 

  5. Tokuda N, Naito S, Matsuzaki O et al (2006) Collecting duct (Bellini duct) renal cell carcinoma: a nationwide survey in Japan. J Urol 176:40–43

    Article  PubMed  Google Scholar 

  6. Oudard S, Banu E, Vieillefond A et al (2007) Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d’Etudes des Tumeurs Uro-Génitales) study. J Urol 177:1698–1702

    Article  PubMed  CAS  Google Scholar 

  7. Chao D, Zisman A, Pantuck AJ (2002) Collecting duct renal cell carcinoma: clinical study of a rare tumor. J Urol 167:71–74

    Article  PubMed  Google Scholar 

  8. Rini BI, Flaherty K (2008) Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma. Urol Oncol 26:543–549

    PubMed  CAS  Google Scholar 

  9. Choueiri TK, Plantade A, Elson P et al (2008) Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 26:127–131

    Article  PubMed  CAS  Google Scholar 

  10. Ansari J, Fatima A, Chaudhri S et al (2009) Sorafenib induces therapeutic response in a patient with metastatic collecting duct carcinoma of kidney. Onkologie 32:44–46

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Hideaki Miyake.

About this article

Cite this article

Miyake, H., Haraguchi, T., Takenaka, A. et al. Metastatic collecting duct carcinoma of the kidney responded to sunitinib. Int J Clin Oncol 16, 153–155 (2011). https://doi.org/10.1007/s10147-010-0116-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-010-0116-z

Keywords

Navigation